Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women

Medical Microbiology and Immunology

Volumn 203, Issue 3, 2014, Pages 177-184

  Cannella, Fabiana ^a   Scagnolari, Carolina ^a   Selvaggi, Carla ^a   Stentella, Patrizia ^b   Recine, Nadia ^b   Antonelli, Guido ^a   Pierangeli, Alessandra ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

HPV infection; IFN lambda; ISG15; Squamous intraepithelial lesion

Indexed keywords

INTERLEUKIN 29; INTERLEUKIN RECEPTOR; VIRUS DNA; CYTOKINE RECEPTOR; IFNLR1 PROTEIN, HUMAN; IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOLOGY; DISEASE COURSE; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENOTYPE; HIGH RISK PATIENT; HUMAN; INNATE IMMUNITY; LOW RISK PATIENT; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNIVERSITY HOSPITAL; UTERINE CERVIX; WART VIRUS; ADOLESCENT; BIOSYNTHESIS; CLASSIFICATION; GENE EXPRESSION PROFILING; IMMUNOLOGY; ISOLATION AND PURIFICATION; ITALY; MIDDLE AGED; PAPILLOMA VIRUS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; GENE EXPRESSION PROFILING; HOSPITALS, UNIVERSITY; HUMANS; INTERLEUKINS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RECEPTORS, CYTOKINE; ROME; YOUNG ADULT;

EID: 84902261904     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-014-0330-9     Document Type: Article

References (31)

1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890-907 (Pubitemid 47371147)
2. Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D (2009) Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 9:347-356. doi:10.1016/S1473-3099(09) 70108-2
3. Stanley MA (2012) Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev 25:215-222. doi:10.1128/CMR.05028-11
4. Ronco LV, Karpova AY, Vidal M, Howley PM (1998) Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 12:2061-2072 (Pubitemid 28323879)
5. Barnard P, McMillan NA (1999) The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 259:305-313 (Pubitemid 29393381)
6. Hong S, Mehta KP, Laimins LA (2011) Suppression of STAT -1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J Virol 85:486-9494. doi:10.1128/JVI. 05007-11
7. Donnelly RP, Kotenko SV (2010) Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 30:555-564. doi:10.1089/jir 2010.0078
8. Kotenko SV, Gallagher G, Baurin V, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4:69-77 (Pubitemid 36109115)
9. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J et al (2003) IL28, IL29 and their class II cytokine receptor IL28R. Nat Immunol 4:63-68 (Pubitemid 36104710)
10. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R (2007) Type III interferon (IFN) induces a type I IFNlike response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81:7749-7758 (Pubitemid 47047861)
11. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM (2006) Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131:1887-1898 (Pubitemid 44958521)
12. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR (2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80:4501-4509
13. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, Dagnaes-Hansen F, Thomsen AR, Chen Z, Haugen H et al (2008) An important role for type III interferon (IFNlambda/IL-28) in TLR-induced antiviral activity. J Immunol 180:2474-2485
14. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA (2011) Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol. doi:10.1155/2011/349575
15. Liu D, Chang CH, Rossi EA, Cardillo TM, Goldenberg DM (2013) Interferon-ë1 linked to a stabilized dimer of fab potently enhances both antitumor and antiviral activities in targeted cells. PLoS One. doi:10.1371/journal.pone.0063940
16. Sommereyns C, Paul S, Staeheli P, Michiels T (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. doi:10.1371/journal.ppat.1000017
17. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, Sorgeloos F, Ehl S, Mayer D, Kochs G et al (2010) Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 84:5670-5677. doi:10.1128/JVI.00272-10
18. Iversen MB, Ank N, Melchjorsen J, Paludan SR (2010) Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs. J Virol 84:4579-4586. doi:10.1128/JVI.02591-09
19. .Reiser J, Hurst J, Voges M, Krauss P, Münch P, Iftner T, Stubenrauch F (2011) High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol 85:11372-11380. doi:10.1128/JVI.05279-11
20. Verteramo R, Pierangeli A, Calzolari E, Patella A, Recine N, Mancini E, Marcone V, Masciangelo R, Bucci M, Antonelli G et al (2006) Direct sequencing of HPV DNA detected in gynaecologic outpatients in Rome, Italy. Microbes Infect 8:2517-2521 (Pubitemid 44499052)
21. Pierangeli A, Degener AM, Ferreri ML, Riva E, Rizzo B, Turriziani O, Luciani S, Scagnolari C, Antonelli G (2011) Interferoninduced gene expression in cervical mucosa during human papillomavirus infection. Int J Immunopathol Pharmacol 24:217-223
22. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, Kebadze T, Mallia P, Stanciu LA, Parker HL (2006) Role of deficient type III interferon-λ production in asthma exacerbations. Nat Med 12:1023-1026 (Pubitemid 44353382)
23. .Scagnolari C, Midulla F, Selvaggi C, Monteleone K, Bonci E, Papoff P, Cangiano G, Di Marco P, Moretti C, Pierangeli A et al (2012) Evaluation of viral load in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. Med Microbiol Immunol 201:311-317. doi:10.1007/s00430-012-0233-6
24. Daud II, Scott ME (2008) Validation of reference genes in cervical cell samples from human papillomavirus-infected and -uninfected women for quantitative reverse transcription-PCR assays. Clin Vaccine Immunol 15:1369-1373. doi:10.1128/CVI.00074-08
25. Castle PE (2009) The evolving definition of carcinogenic human papillomavirus. Infect Agent Cancer 11:4-7. doi:10.1186/1750-9378-4-7
26. Haller O, Kochs G (2011) Human MxA protein: an interferoninduced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 31:79-87. doi:10.1089/jir 2010.0076
27. Durfee LA, Lyon N, Seo K et al (2010) The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol Cell 11(38):722-732. doi:10.1016/j.molcel.2010.05.002
28. .Terenzi F, Saikia P, Sen GC (2008) Interferon-inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1. EMBO J 27:3311-3321. doi:10.1038/emboj.2008.241
29. Weinstock-Guttman B, Tamano-Blanco M, Bhasi K (2007) Pharmacogenetics of MxA SNPs in interferon-beta treated multiple sclerosis patients. J Neuro Immunol 128:879-886
30. Scagnolari C, Antonelli G (2013) Antiviral activity of the interferon á family: biological and pharmacological aspects of the treatment of chronic hepatitis C. Expert Opin Biol Ther 5:693-711
31. Pitha-Rowe IF, Pitha PM (2007) Viral defense, carcinogenesis and ISG15: novel roles for an old ISG. Cytokine Growth Factor Rev 104:1371-1376